
HIV patients who persistently use cocaine and heroin face a greater risk of opportunistic infections, disease progression, and death compared with HIV patients who do not use drugs, according to a new study.
Gregory M. Lucas of the Johns Hopkins University School of Medicine and colleagues used confidential computer-based interviews to survey patients in Baltimore at six-month intervals beginning in 1998. The study's 1,851 participants included 1,028 nonusers, 588 intermittent users (drug use for an average of 14 days in the previous six months), and 235 persistent users (drug use for an average of 27 days in the previous six months). At three years, the estimated survival rate was 68% for persistent users, 80% for intermittent users, and 87% for nonusers.
After the researchers adjusted for age, race, gender, lowest CD4-cell count, and highest HIV level, they found the risk of death was almost twice as high in intermittent users and close to three times as high in persistent users. During periods of abstinence from drug use, however, the risk of new opportunistic infections was near that of nonusers. When intermittent users were actively using drugs, their risk was closer to that of persistent users. The researchers noted similar risks for progression of HIV disease.
Lucas and colleagues suggested that the effects of drug use on disease progression may be related to increased viral replication, impaired lymphocyte function, reduced access to care, and poor adherence to drug therapy.
For patients who use heroin or cocaine, the authors recommended a treatment program that links HIV, substance abuse, and psychiatric treatment. Buprenorphine therapy for opioid dependence may help these patients, the researchers wrote. (Reuters)
These comments are reproduced as written by visitors to this Web site. They have not been edited for content, grammar, or spelling. The viewpoints appearing here are those of the writer, and do not necessarily reflect the opinion or views of advocate.com, The Advocate, or its affiliates.
Be the first to comment on this story.
If you would like to submit a comment for posting, please fill out the form above.
All comments submitted via this form are subject to posting or publication. (To send a private letter to an Advocate editor or writer, please use the e-mail button at the top of the page, or use snail mail.) If you would like your comment considered for publication in The Advocate magazine, please include your full name, your city of residence, and a phone number where you can be reached during business hours so that we can confirm your identity. Your e-mail address and telephone number are strictly confidential and will not be shared or used for any purpose other than to contact you about your comment.
See the Contact page for sending comments for reasons other than responding to Advocate editorial and news stories.
Please note that comments sent by fax or snail mail are unlikely to be posted, although they will be considered for publication along with all letters received via e-mail or via this Web page. Comments that chiefly concern Advocate.com content will be considered for posting only on the Web site. The Advocate reserves the right to edit submitted comments for grammar, spelling, obscenities, or libel; we will, however, do our best to preserve the original comment's style and intent. Comments considered for publication in The Advocate magazine may also be edited for length.